MMWR Morb Mortal Wkly Rep. 2011 Jul 8;60(26):878-83.
Initiation of contraception during the postpartum period is important to prevent unintended pregnancy and short birth intervals, which can lead to negative health outcomes for mother and infant. In 2010, CDC published U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 (US MEC), providing evidence-based guidance for choosing a contraceptive method based on the relative safety of contraceptive methods for women with certain characteristics or medical conditions, including women who are postpartum. Recently, CDC assessed evidence regarding the safety of combined hormonal contraceptive use during the postpartum period. This report summarizes that assessment and the resulting updated guidance. These updated recommendations state that postpartum women should not use combined hormonal contraceptives during the first 21 days after delivery because of the high risk for venous thromboembolism (VTE) during this period. During 21-42 days postpartum, women without risk factors for VTE generally can initiate combined hormonal contraceptives, but women with risk factors for VTE (e.g., previous VTE or recent cesarean delivery) generally should not use these methods. After 42 days postpartum, no restrictions on the use of combined hormonal contraceptives based on postpartum status apply.
产后立即开始避孕对于防止意外怀孕和缩短生育间隔非常重要,因为这可能会对母婴健康造成负面影响。2010 年,CDC 发布了《美国避孕医学资格标准》(US MEC),为根据具有某些特征或医疗条件的女性(包括产后女性)选择避孕方法提供了基于避孕方法相对安全性的循证指导。最近,CDC 评估了产后使用复方激素避孕药的安全性证据。本报告总结了这一评估和由此产生的更新指导意见。这些更新的建议指出,由于产后 21 天内静脉血栓栓塞(VTE)的风险很高,产后女性不应该在此期间使用复方激素避孕药。在产后 21-42 天期间,没有 VTE 风险因素的女性通常可以开始使用复方激素避孕药,但有 VTE 风险因素的女性(例如,既往 VTE 或近期剖宫产)通常不应使用这些方法。产后 42 天后,不根据产后状态限制使用复方激素避孕药。